Partner Perspectives To De-Risk Commercialization Of Combination Products

Developing an effective drug-device combination product for self-administered biologics is a complex process.

It requires critical decisions during delivery system selection. Making the right choices at an early stage can reduce risks throughout your drug development journey. Ultimately, a well-executed strategy will help support integration with manufacturing operations and successful drug delivery.

During this webinar, Becton Dickinson and PCI Pharma Services shared insights on topics including:

  • Design space evolution and potential trade-offs when selecting device components for combination products
  • Approaches to de-risk your drug delivery system
  • Factor to consider when selecting a CDMO for secondary device assembly with biologics
  • Insights into how your delivery system and key partners can support successful commercialization of your combination product.

Partner Perspectives To De-Risk Commercialization Of Combination Products

To view this webinar, please complete the form below;

When it comes to pharmaceutical and biopharmaceutical supply chain expertise who do you trust?

Your bridge between life-changing therapies and patients